Primary results from post hoc analysis of the apollo-b brazilian subpopulation, a phase 3 study of patisiran in patients with transthyretin amyloidosis with cardiomyopathy
Arq. bras. cardiol; 121 (9 supl.1), 2024
BACKGROUND: Transthyretin amyloidosis (ATTR) is a progressive, fatal disease caused by toxic misfolded transthyretin (TTR) amyloid deposits. Patisiran, an RNA interference therapeutic, inhibits synthesis of wild-type and variant TTR and is approved for the treatment of hereditary ATTR with polyneuropathy...